Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing

Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Rita Dias Branda˜o Kees van Roozendaal Demis Tserpelis Encarna Go´mez Garcı´a Marinus J. Blok
  • چاپ و سال / کشور: 2011

Description

subset of the unclassified variants (UVs) identified during genetic screening of BRCA1/2 genes may affect splicing. We assessed at RNA level the effect of four BRCA1 and ten BRCA2 UVs with a putative splice effect, as predicted in silico. The variants selected for this study were beyond the positions -1, -2 or ?1, ?2 from the exon, and were not previously described (n = 8) or their effect on splicing was not assessed previously (n = 6). Lymphocytes from UV carriers and healthy controls were cultured and treated with puromycin to prevent nonsense-mediated mRNA decay. The relative contribution of each allele to the various transcripts was assessed using combinations of allele-specific and transcript- specific primers.BRCA2 c.425G[T, c.7976?3_7976? 4del and c.8754?3G[C give rise to aberrant transcripts BRCA2D4, BRCA2D17 and retention of 46nt of intron 21, respectively, and were considered pathogenic. BRCA1 c.4987-3C[G gives rise to BRCA1D17 that is likely pathogenic; however, residual expression of the full-length transcript from the variant allele could not be excluded. BRCA1 c.692C[T, c.693G[A and BRCA2 c.6935A[T, besides expressing the full-length transcript, increased expression of BRCA1D11 and BRCA2D12, respectively. As these are naturally occurring isoforms, also observed in controls, the clinical relevance is unclear.The seven remainingUVs did not affect splicing and three intronic variants were therefore classified as neutral. In conclusion, the RNA analysis results clarified the clinical relevance of 6 of the 14 studied UVs and thereby greatly improve the genetic counselling of high-risk breast/ovarian cancer patients carrying these classified variants.
Breast Cancer Res Treat DOI 10.1007/s10549-011-1599-7 Received: 22 March 2011 / Accepted: 14 May 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری